About 22nd Century Group, Inc - Common Stock (XXII)
22nd Century Group Inc is a biotechnology company focused on the development and commercialization of plant-based products, particularly in the areas of hemp and cannabis, as well as products that reduce nicotine levels in tobacco. The company leverages its proprietary genetic technologies to create innovative solutions within these sectors, aiming to transform the way consumers interact with tobacco and cannabis products while promoting public health. Additionally, 22nd Century seeks to advance research and product offerings that cater to a growing demand for reduced-risk alternatives and sustainability in agriculture. Read More
22nd Century Group (Nasdaq: XXII) announced it has signed two new agreements with former customers to supply filtered cigar products, expanding its contract manufacturing operations. The company expects to begin shipments in the second quarter of 2025, with anticipated annual volumes of at least 500,000 cartons. The deals are part of 22nd Century’s broader strategy to grow its core manufacturing business while reinforcing its long-term goal of expanding VLN® low-nicotine products through established retail channels.
22nd Century stock is moving higher on Monday after the company announced its readiness to support the FDA's proposed standard to mandate reduced nicotine content in cigarettes.
